Evaluation of Triple Fragment Vaccine HSPX (Rv۲۰۳۱c) + PPE۴۴ (Rv۲۷۷۰c) + Mouse IgG۱ (Fcγ۲a) with Auxiliary Adjuncts IL-۲۲ in Comparison with BCG Vaccine

Publish Year: 1401
نوع سند: مقاله ژورنالی
زبان: English
View: 159

This Paper With 11 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_IJP-17-3_007

تاریخ نمایه سازی: 8 شهریور 1401

Abstract:

Background & Objective: Despite the vaccination with the BCG vaccine, tuberculosis (TB) remains one of the major health problems in the world. The aim of this study was to evaluate our newly designed vaccine using IL-۲۲ as an adjuvant in comparison with the common BCG vaccine.Methods: The gene constructs were cloned into the expression vector of pET۲۸a and then into the recombinant vector of PET۲۸a – HSPX, and PPE۴۴ was transformed into Escherichia coli BL۲۱ (DE۳). Finally, the immunogenicity of recombinant proteins with and without BCG and IL-۲۲ in BALB/c mice was investigated.Results: The key cytokines INF-γ and TNF-α were elevated more greatly in BCG immunized group than in PHF immunized group.Immunization with PHF showed a significant increase in IL-۴ levels versus the BCG group. Adding IL-۲۲ to the vaccine formulations indicated a tiny increase in IL-۴ levels compared to their related vaccine groups.Specific total IgG۱ in the experimental groups showed an increase in comparison with control groups, but in the vaccinated groups, no significant differences were observed, and the presence of IL-۲۲ in the vaccine formulations indicated a slight decrease compared with the related mere vaccine groups. Results of specific total IgG۲a in the experimental groups revealed that only in the PHF group formulated with IL-۲۲ a significant increase occurs compared with all other experimental groups.Conclusion: It seems that BCG, as the only licensed vaccine for TB infection, could be more potent than a recombinant vaccine in the induction of cellular and humoral immune responses.

Authors

Azar valizadeh

Clinical Microbiology Research Center, Ilam University of Medical Sciences, Ilam, Iran.

Fra Khosravi

Clinical Microbiology Research Center, Ilam University of Medical Sciences, Ilam, Iran

hamid sedighian

Applied Microbiology Research Center, Systems biology and poisonings institute, Baqiyatallah University of Medical Sciences, Tehran, Iran

Elham Behzadi

Academy of Medical Sciences of the IR of Iran, Tehran, Iran

Elaheh Parizad

Clinical Microbiology Research Center, Ilam University of Medical Sciences, Ilam, Iran.

Abbas Ali Imani Fooladi

Applied Microbiology Research Center, Systems biology and poisonings institute, Baqiyatallah University of Medical Sciences, Tehran, Iran

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • Gicquel B. Towards new mycobacterial vaccines. Dev Biol Stand. ۱۹۹۴;۸۲:۱۷۱-۸ ...
  • Lawn SD. Alimuddin. Tuberculosis Lancet. ۲۰۱۱;۳۷۸:۵۷-۷۲. [DOI:۱۰.۱۰۱۶/S۰۱۴۰-۶۷۳۶(۱۰)۶۲۱۷۳-۳]Dara M, Dadu A, ...
  • Yuan W, Dong N, Zhang L, Liu J, Lin S, ...
  • Farsiani H, Mosavat A, Soleimanpour S, Sadeghian H, Akbari Eydgahi ...
  • Mekhaiel DN, Czajkowsky DM, Andersen JT, Shi J, El-Faham M, ...
  • نمایش کامل مراجع